Artelo Biosciences and University of Western Ontario Awarded Research Grant by Mitacs
November 23, 2020 08:30 ET
|
Artelo Biosciences
LA JOLLA, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate...
Artelo Biosciences Announces Clinical Trial Authorization to Commence Cancer Appetite Recovery Study for the Treatment of Cancer-Related Anorexia and Weight Loss
November 16, 2020 08:30 ET
|
Artelo Biosciences
First patients on track for enrollment this year Targeting multi-billion market with no approved therapies for cancer-related anorexia LA JOLLA, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) --...
Artelo Biosciences Reports Fourth Quarter and Fiscal 2020 Year-End Financial Results and Provides Business Update
November 04, 2020 08:00 ET
|
Artelo Biosciences
Closed $7.6 Million Underwritten Public Offering Received Ethics Approval to Commence CAReS Study of ART27.13 in the UKExpanded Exclusive Worldwide License with Stony Brook University for Fatty Acid...
Artelo Biosciences Files Patent on Use of Fatty Acid Binding Protein 5 Inhibitors for Treating Psychological Disorders
October 21, 2020 08:30 ET
|
Artelo Biosciences
LA JOLLA, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended...
Artelo Biosciences, Inc. Announces Closing of $7.6 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option
October 14, 2020 16:05 ET
|
Artelo Biosciences
LA JOLLA, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended...
Artelo Biosciences, Inc. Announces Pricing of $6.6 Million Upsized Underwritten Public Offering
October 09, 2020 08:30 ET
|
Artelo Biosciences
LA JOLLA, Calif., Oct. 09, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended...
Artelo Biosciences Receives Ethics Approval to Commence its Cancer Appetite Recovery Phase I/II Clinical Study (CAReS) of ART27.13 for the Treatment of Cancer-Related Anorexia
September 29, 2020 08:00 ET
|
Artelo Biosciences
LA JOLLA, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the...
Artelo Biosciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15th
September 11, 2020 09:00 ET
|
Artelo Biosciences
LA JOLLA, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid...
Artelo Biosciences to Participate in Two Keynote Panels at 3rd Annual International Cannabinoid Derived Pharmaceutical Summit
September 10, 2020 09:15 ET
|
Artelo Biosciences
LA JOLLA, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid...
Artelo Biosciences Reports Third Quarter Fiscal Year 2020 Financial Results and Provides Business Update
July 14, 2020 09:25 ET
|
Artelo Biosciences
LA JOLLA, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the...